Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma-Reply

Affiliations

Comment

Rui Guo et al. JAMA. 2023.

. 2023 Jan 17;329(3):261-262.

doi: 10.1001/jama.2022.21036.

¹ Sun Yat-Sen University Cancer Center, The State Key Laboratory of Oncology in South China, Guangzhou, China.

No abstract available

Comment on

Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma.
Lin TA, Wei LJ, Ludmir EB. Lin TA, et al. JAMA. 2023 Jan 17;329(3):261. doi: 10.1001/jama.2022.21033. JAMA. 2023. PMID: 36648473 No abstract available.
Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma.
Hu YT, Kao YS. Hu YT, et al. JAMA. 2023 Jan 17;329(3):260. doi: 10.1001/jama.2022.21030. JAMA. 2023. PMID: 36648474 No abstract available.
Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy and Survival of Patients With Low-Risk Nasopharyngeal Carcinoma.
Liu Y, Zhang Y. Liu Y, et al. JAMA. 2023 Jan 17;329(3):260-261. doi: 10.1001/jama.2022.21027. JAMA. 2023. PMID: 36648475 No abstract available.